Field Trip Health (FTRP) Granted US Patent Covering Novel Psychedelic Molecule FT-104
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Oil drops more than $2 despite new US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- RUM Group signs $13.7 billion GPU services deal, issues warrants
- Grand Canyon Education places CFO on leave amid stock trade probe
- Funds sell $44bn in semiconductors on AI concerns
Field Trip Health Ltd. Granted US Patent Covering Novel Psychedelic Molecule FT-104
April 5, 2022 7:51 AM EDTTORONTO, April 05, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (NASDAQ: FTRP, TSX: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, today announced that the U.S. Patent and Trademark Office (USPTO) has granted the Company a patent for claims related to FT-104 (informally known as Isoprocin Glutarate), Field Trips first novel psychedelic molecule in development.
Claims in the patent application titled, Tryptamine Prodrugs, grant exclusive rights to Field Trip for the composition of matter, use and manufacturing of a family of hemi-ester compounds of hydroxytryptamines,... More
